Daiichi Sankyo Limited (DSKYF)
22.05
1.47 (7.14%)
At close: Apr 21, 2025, 3:25 PM
7.14% (1D)
| Bid | 20.55 |
| Market Cap | 40.62B |
| Revenue (ttm) | 1,687B |
| Net Income (ttm) | 229.1B |
| EPS (ttm) | 0.9 |
| PE Ratio (ttm) | 24.5 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 23.55 |
| Volume | 29,905 |
| Avg. Volume (20D) | 68,701 |
| Open | 23.39 |
| Previous Close | 20.58 |
| Day's Range | 20.62 - 24.62 |
| 52-Week Range | 20.15 - 44.64 |
| Beta | 0.33 |
About DSKYF
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders;...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 24, 2008
Employees 18,726
Stock Exchange PNK
Ticker Symbol DSKYF
Website https://www.daiichisankyo.com
2 months ago · seekingalpha.com
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call TranscriptDaiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Koji Ogawa -...